Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials
- 1 July 2009
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 68 (7) , 1177-1183
Abstract
Purpose: Tumour necrosis factor (TNF) plays an important role in inflammation and may affect tumour growth control. To assess the risk of malignancy with etanercept, a fusion protein that inhibits TNF action, a meta-analysis was performed using individual patient data from randomised controlled trials (RCT) in patients with rheumatoid arthritis (RA). Methods: A search was conducted of bibliographic databases, abstracts from annual meetings and any unpublished studies on file with manufacturers of etanercept to December 2006. Only RCT of etanercept used for 12 weeks or more in patients with RA were included. Nine trials met the inclusion criteria. To adjudicate endpoints, the case narratives of potential cases were reviewed. Patient-level data were extracted from the clinical trials databases. Results: The nine trials included 3316 patients, 2244 who received etanercept (contributing 2484 person-years of follow-up) and 1072 who received control therapy (1051 person-years). Malignancies were diagnosed in 26 patients in the etanercept group (incidence rate (IR) 10.47/1000 person-years) and seven patients in the control group (IR 6.66/1000 person-years). A Cox’s proportional hazards, fixed-effect model stratified by trial yielded a hazard ratio of 1.84 (95% CI 0.79 to 4.28) for the etanercept group compared with the control group. Conclusions: In this analysis, the point estimate of malignancy risk was higher in etanercept-treated patients, although the results were not statistically significant. The approach of obtaining individual patient data of RCT in cooperation with trial sponsors allowed important insights into the methodological advantages and challenges of sparse adverse event data meta-analysis.Keywords
This publication has 30 references indexed in Scilit:
- Malignancy and rheumatoid arthritisCurrent Rheumatology Reports, 2007
- Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational studyArthritis & Rheumatism, 2007
- Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis—ReplyJAMA, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: Two‐year clinical and radiographic results from the TEMPO study, a double‐blind, randomized trialArthritis & Rheumatism, 2006
- What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse dataStatistics in Medicine, 2004
- Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomesArthritis & Rheumatism, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hipArthritis & Rheumatism, 1991
- Tables of the number of patients required in clinical trials using the logrank testStatistics in Medicine, 1982